Modified cariprazine relapse prevention clinical trial results

Our study, “Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial,” was previously published in Schizophrenia Research (Durgam et al., 2016). As a courtesy, we would like to alert your readers that some of the publ ished results from this study (RGH-MD-06) differ slightly from information in the cariprazine (VRAYLAR©) package insert (Vraylar [package insert], 2017). Due to results of additional analyses requested by the US FDA, the Kaplan-Meier cumulative rate of relapse curve in the VRAYLAR package insert (F ig.
Source: Schizophrenia Research - Category: Psychiatry Authors: Tags: Letter to the Editor Source Type: research